Physician profile
Stuart Alan Kauffman
NPI 1124137088
$3,780.70
in general payments reported to CMS, 2019-2025
27 companies · $14.51 in 2025
The $14.51 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,302 · 2020: $300 · 2021: $21.29 · 2024: $144 · 2025: $14.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,907.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $598.81 | 2019-2020 | |
| Liberty Surgical INC. | $195.24 | 2019 | |
| Eisai INC. | $114.13 | 2024 | |
| Scilex Pharmaceuticals INC. | $112.52 | 2019-2020 | |
| Lilly USA, LLC | $104.72 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $91.54 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.04 | 2019 | |
| Pfizer INC. | $82.11 | 2019 | |
| Orexo US, INC. | $64.16 | 2019 | |
| Novo Nordisk INC | $60.56 | 2019 | |
| West Therapeutics Development, LLC | $40.45 | 2019 | |
| Amarin Pharma, INC. | $40.33 | 2020 | |
| Avanir Pharmaceuticals, INC. | $37.16 | 2019 | |
| Bausch Health US, LLC | $34.74 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30.82 | 2019 | |
| Exact Sciences Corporation | $29.45 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $28.88 | 2019-2020 | |
| Janssen Biotech, INC. | $16.50 | 2019 | |
| Shionogi INC | $15.15 | 2019 | |
| Dexcom, INC. | $14.51 | 2025 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $14.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.21 | 2019 | |
| Fidia Pharma USA INC. | $13.06 | 2019 | |
| Allergan, INC. | $11.50 | 2019 | |
| Horizon Therapeutics Plc | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Kauffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.